{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:43:32Z","timestamp":1772210612162,"version":"3.50.1"},"reference-count":207,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1590\/0074-02760150239","type":"journal-article","created":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T22:31:20Z","timestamp":1446935480000},"page":"847-864","source":"Crossref","is-referenced-by-count":23,"title":["Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors"],"prefix":"10.1590","volume":"110","author":[{"given":"Lucianna Helene","family":"Santos","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Salgado","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto Ra\u00fal","family":"Caffarena","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/cr040426m","article-title":"Molecular dynamics: survey of methods for simulating the activity of proteins","volume":"106","author":"Adcock SA","year":"2006","journal-title":"Chem Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.39.6.1329","article-title":"The PETT series, a new class of potent nonnucleoside inhibitors of human-immunodeficiency-virus type-1 reverse-transcriptase","volume":"39","author":"Ahgren C","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcc.23905","article-title":"DOCK 6: impact of new features and current docking performance","volume":"36","author":"Allen WJ","year":"2015","journal-title":"J Comput Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/med.20067","article-title":"Combining docking and molecular dynamic simulations in drug design","volume":"26","author":"Alonso H","year":"2006","journal-title":"Med Res Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1386207013330661","article-title":"The linear interaction energy method for predicting ligand binding free energies","volume":"4","author":"Aqvist J","year":"2001","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1128\/AAC.00591-12","article-title":"Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors","volume":"56","author":"Asahchop EL","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00044-014-1141-7","article-title":"In-silico design and study of novel piperazinyl beta-carbolines as inhibitor of HIV-1 reverse transcriptase","volume":"24","author":"Ashok P","year":"2015","journal-title":"Med Chem Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ptr.1629","article-title":"Naturally derived anti-HIV agents","volume":"19","author":"Asres K","year":"2005","journal-title":"Phytother Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s00044-013-0753-7","article-title":"Comparative molecular docking studies of novel 3, 5-disubstituted thiazolidinedione analogs as HIV-1-RT inhibitors","volume":"23","author":"Bahare RS","year":"2014","journal-title":"Med Chem Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.bmcl.2004.09.068","article-title":"QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors","volume":"14","author":"Balaji S","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1021\/ci700271z","article-title":"Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking and MM-GB\/SA scoring","volume":"47","author":"Barreiro G","year":"2007","journal-title":"J Chem Inf Model"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/jm070683u","article-title":"From docking false-positive to active anti-HIV agent","volume":"50","author":"Barreiro G","year":"2007","journal-title":"J Med Chem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barre-Sinoussi F","year":"1983","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"D1083","DOI":"10.1093\/nar\/gkt1031","article-title":"The ChEMBL bioactivity database: an update","volume":"42","author":"Bento AP","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref15","first-page":"36","article-title":"In silico prediction of ADME properties: are we making progress?","volume":"7","author":"Beresford AP","year":"2004","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman HM","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1021\/jm201134m","article-title":"Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents","volume":"54","author":"Bollini M","year":"2011","journal-title":"J Med Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.drudis.2009.01.003","article-title":"Managing protein flexibility in docking and its applications","volume":"14","author":"B-Rao C","year":"2009","journal-title":"Drug Discov Today"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder S","year":"2010","journal-title":"Antiviral Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2009.10.013","article-title":"Development of topical microbicides to prevent the sexual transmission of HIV","volume":"85","author":"Buckheit RW","year":"2010","journal-title":"Antiviral Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2174\/0929867321666140120121158","article-title":"Recent progress in the research of small molecule HIV-1 RNase H inhibitors","volume":"21","author":"Cao L","year":"2014","journal-title":"Curr Med Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0026-895X(24)23192-8","article-title":"Accommodating protein flexibility in computational drug design","volume":"57","author":"Carlson HA","year":"2000","journal-title":"Mol Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2174\/156802607780906753","article-title":"Ligand docking and structure-based virtual screening in drug discovery","volume":"7","author":"Cavasotto CN","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/157340908785747474","article-title":"Docking and high throughput docking: successes and the challenge of protein flexibility","volume":"4","author":"Cavasotto N","year":"2008","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00044-014-1251-2","article-title":"Structure-based virtual screening and docking studies for the identification of novel inhibitors against wild and drug resistance strains of HIV-1 RT","volume":"24","author":"Chander S","year":"2015","journal-title":"Med Chem Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1007\/BF02854894","article-title":"Drug discovery from natural sources","volume":"8","author":"Chin YW","year":"2006","journal-title":"AAPS J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","article-title":"Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine","volume":"85","author":"Cihlar T","year":"2010","journal-title":"Antiviral Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/jmbi.2001.4551","article-title":"FlexE: efficient molecular docking considering protein structure variations","volume":"308","author":"Claussen H","year":"2001","journal-title":"J Mol Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/ja00124a002","article-title":"A 2nd generation force-field for the simulation of proteins, nucleic-acids and organic-molecules","volume":"117","author":"Cornell WD","year":"1995","journal-title":"J Am Chem Soc"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1021\/jm901167t","article-title":"Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase","volume":"52","author":"Cullen MD","year":"2009","journal-title":"J Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/jm049798d","article-title":"Comparison of automated docking programs as virtual screening tools","volume":"48","author":"Cummings MD","year":"2005","journal-title":"J Med Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3565(25)21172-7","article-title":"Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1","volume":"279","author":"Currens MJ","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das K","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1021\/jm101536x","article-title":"Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket","volume":"54","author":"Das K","year":"2011","journal-title":"J Med Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das K","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)","volume":"85","author":"de Bethune MP","year":"2010","journal-title":"Antiviral Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/med.20153","article-title":"Another ten stories in antiviral drug discovery (Part C): \u201cold\u201d and \u201cnew\u201d antivirals, strategies and perspectives","volume":"29","author":"De Clercq E","year":"2009","journal-title":"Med Res Rev"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","volume":"10","author":"De Clercq E","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1021\/jp807701h","article-title":"Computations of standard binding free energies with molecular dynamics simulations","volume":"113","author":"Deng YQ","year":"2009","journal-title":"J Phys Chem B"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1006\/jmbi.1998.2208","article-title":"Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution","volume":"284","author":"Ding J","year":"1998","journal-title":"J Mol Biol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nsb0595-407","article-title":"Structure of HIV-1 RT\/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors","volume":"2","author":"Ding J","year":"1995","journal-title":"Nat Struct Biol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin R","year":"2011","journal-title":"Science"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmech.2012.01.056","article-title":"Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape, 2D-fingerprint and pharmacophore-based virtual screening approach","volume":"50","author":"Distinto S","year":"2012","journal-title":"Eur J Med Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.2174\/1381612811319100009","article-title":"Molecular aspects of the RT\/drug interactions. Perspective of dual inhibitors","volume":"19","author":"Distinto S","year":"2013","journal-title":"Curr Pharm Des"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"13754","DOI":"10.1039\/C4RA15397A","article-title":"Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations","volume":"5","author":"Dong M","year":"2015","journal-title":"RSC Adv"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/138620706776055539","article-title":"Computational methods in developing quantitative structure-activity relationships (QSAR): a review","volume":"9","author":"Dudek AZ","year":"2006","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/ja993663t","article-title":"Prediction of properties from simulations: free energies of solvation in hexadecane, octanol and water","volume":"122","author":"Duffy EM","year":"2000","journal-title":"J Am Chem Soc"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/ci600288m","article-title":"Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities","volume":"47","author":"Ehrman TM","year":"2007","journal-title":"J Chem Inf Model"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/ci400040d","article-title":"Docking challenge: protein sampling and molecular docking performance","volume":"53","author":"Elokely KM","year":"2013","journal-title":"J Chem Inf Model"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1073\/pnas.94.8.3984","article-title":"Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor","volume":"94","author":"Esnouf RM","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/586401","article-title":"HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors and new inhibitors with innovative mechanisms of actions","volume":"2012","author":"Esposito F","year":"2012","journal-title":"Mol Biol Int"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1742-4658.2011.08057.x","article-title":"Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases","volume":"278","author":"Esposito F","year":"2011","journal-title":"FEBS J"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1011115820450","article-title":"DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases","volume":"15","author":"Ewing TJ","year":"2001","journal-title":"J Comput Aided Mol Des"},{"key":"ref54","series-title":"Antiretroviral drugs used in the treatment of HIV infection","year":"2014"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/187152908786786232","article-title":"Cardiovascular effects of antiretroviral drugs: clinical review","volume":"8","author":"Filardi PP","year":"2008","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/ci400427a","article-title":"Assessing molecular focking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs","volume":"53","author":"Fraczek T","year":"2013","journal-title":"J Chem Inf Model"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner RA","year":"2004","journal-title":"J Med Chem"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/157340909789577847","article-title":"Molecular dynamics as a tool in rational drug design: current status and some major applications","volume":"5","author":"Galeazzi R","year":"2009","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner MR","year":"2015","journal-title":"Nature"},{"key":"ref60","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.17.4.19532","article-title":"Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF\/FTC in ART-naive HIV-positive patients","volume":"17","author":"Gatell JM","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1020280627193","article-title":"HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures","volume":"16","author":"Gaudio AC","year":"2002","journal-title":"J Comput Aided Mol Des"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bmc.2003.12.031","article-title":"QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters","volume":"12","author":"Gayen S","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1021\/jm200649p","article-title":"Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation and protein-ligand X-ray crystal structure","volume":"54","author":"Ghosh AK","year":"2011","journal-title":"J Med Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh AK","year":"2008","journal-title":"Acc Chem Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/156802611794480927","article-title":"In-silico ADME models: a general assessment of their utility in drug discovery applications","volume":"11","author":"Gleeson MP","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1016\/j.bmcl.2011.10.027","article-title":"Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase","volume":"21","author":"Gomez R","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6","article-title":"Automated docking of flexible ligands: applications of AutoDock","volume":"9","author":"Goodsell DS","year":"1996","journal-title":"J Mol Recognit"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.str.2008.03.009","article-title":"Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins","volume":"16","author":"Gorfe AA","year":"2008","journal-title":"Structure"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1007\/s00044-013-0765-3","article-title":"Computer-assisted design of dual-target anti-HIV-1 compounds","volume":"23","author":"Guimar\u00e3es MC","year":"2014","journal-title":"Med Chem Res"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren TA","year":"2004","journal-title":"J Med Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1021\/ct500161f","article-title":"Practical aspects of free-energy calculations: a review","volume":"10","author":"Hansen N","year":"2014","journal-title":"J Chem Theory Comput"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/prot.20578","article-title":"Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations","volume":"61","author":"He X","year":"2005","journal-title":"Proteins"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1021\/jm800473d","article-title":"Virtual screening, identification and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1","volume":"51","author":"Herschhorn A","year":"2008","journal-title":"J Med Chem"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1128\/AAC.33.6.844","article-title":"Cellular pharmacology of 2\u2019,3\u2019-dideoxy-2\u2019,3\u2019-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus","volume":"33","author":"Ho HT","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/jm960056x","article-title":"Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors","volume":"39","author":"Hopkins AL","year":"1996","journal-title":"J Med Chem"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/jmbi.1998.2171","article-title":"Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance","volume":"284","author":"Hsiou Y","year":"1998","journal-title":"J Mol Biol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0969-2126(96)00091-3","article-title":"Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms","volume":"4","author":"Hsiou Y","year":"1996","journal-title":"Structure"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/prot.21214","article-title":"Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking","volume":"66","author":"Huang SY","year":"2007","journal-title":"Proteins"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC - a free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin JJ","year":"2005","journal-title":"J Chem Inf Model"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jmb.2009.03.037","article-title":"Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations","volume":"388","author":"Ivetac A","year":"2009","journal-title":"J Mol Biol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2174\/138161211796355056","article-title":"Molecular recognition in the case of flexible targets","volume":"17","author":"Ivetac A","year":"2011","journal-title":"Curr Pharm Des"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cbdd.12277","article-title":"Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles","volume":"83","author":"Ivetac A","year":"2014","journal-title":"Chem Biol Drug Des"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson MP","year":"2002","journal-title":"J Mol Biol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson MP","year":"2004","journal-title":"Proteins"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/jm020406h","article-title":"Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine","volume":"46","author":"Jain AN","year":"2003","journal-title":"J Med Chem"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10822-007-9114-2","article-title":"Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility and knowledge-based search","volume":"21","author":"Jain AN","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen PA","year":"2005","journal-title":"J Med Chem"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0022-2836(91)90859-5","article-title":"\u201cSoft docking\u201d: matching of molecular surface cubes","volume":"219","author":"Jiang F","year":"1991","journal-title":"J Mol Biol"},{"key":"ref89","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-9-99","article-title":"A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants","volume":"9","author":"Johnson BC","year":"2012","journal-title":"Retrovirology"},{"key":"ref90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na\u00efve populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson JA","year":"2008","journal-title":"PLoS Med"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1126\/science.1096361","article-title":"The many roles of computation in drug discovery","volume":"303","author":"Jorgensen WL","year":"2004","journal-title":"Science"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen WL","year":"1996","journal-title":"J Am Chem Soc"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/jcph.1999.6201","article-title":"NAMD2: greater scalability for parallel molecular dynamics","volume":"151","author":"Kale L","year":"1999","journal-title":"J Comput Phys"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1039\/C4MB00147H","article-title":"\u201cOld Dogs with New Tricks\u201d: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets","volume":"10","author":"Kang D","year":"2014","journal-title":"Mol Biosyst"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(12)60786-7","article-title":"Antiretroviral prophylaxis for HIV prevention reaches a key milestone","volume":"379","author":"Karim SS","year":"2012","journal-title":"Lancet"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1093-3263(02)00183-3","article-title":"Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor","volume":"21","author":"Keller PA","year":"2003","journal-title":"J Mol Graph Model"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/187152611794407782","article-title":"Development of anti-viral agents using molecular modeling and virtual screening techniques","volume":"11","author":"Kirchmair J","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.bmcl.2007.11.127","article-title":"Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase - structure-activity relationships and crystallographic analysis","volume":"18","author":"Kirschberg TA","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"ref99","first-page":"940","article-title":"Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection","volume":"11","author":"Klibanov OM","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/jmbi.1996.0776","article-title":"Molecular docking to ensembles of protein structures","volume":"266","author":"Knegtel RM","year":"1997","journal-title":"J Mol Biol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1126\/science.1377403","article-title":"Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor","volume":"256","author":"Kohlstaedt LA","year":"1992","journal-title":"Science"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman PA","year":"2000","journal-title":"Acc Chem Res"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8","article-title":"Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking","volume":"37","author":"Kramer B","year":"1999","journal-title":"Proteins"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/138920307781369382","article-title":"Structure-based drug design: docking and scoring","volume":"8","author":"Kroemer RT","year":"2007","journal-title":"Curr Protein Pept Sci"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrd1156","article-title":"Drug research: myths, hype and reality","volume":"2","author":"Kubinyi H","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref106","first-page":"U667","article-title":"Qsar, 3d Qsar and Beyond","volume":"217","author":"Kubinyi H","year":"1999","journal-title":"Abstr Pap Am Chem Soc"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0022-2836(82)90153-X","article-title":"A geometric approach to macromolecule-ligand interactions","volume":"161","author":"Kuntz ID","year":"1982","journal-title":"J Mol Biol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nchem.1559","article-title":"Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase","volume":"5","author":"Kuroda DG","year":"2013","journal-title":"Nat Chem"},{"key":"ref109","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-9-396","article-title":"FAF-Drugs2: free ADME\/tox filtering tool to assist drug discovery and chemical biology projects","volume":"9","author":"Lagorce D","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1098\/rsif.2011.0843","article-title":"Bioinformatics and variability in drug response: a protein structural perspective","volume":"9","author":"Lahti JL","year":"2012","journal-title":"J R Soc Interface"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"16705","DOI":"10.1021\/ja408917n","article-title":"Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group","volume":"135","author":"Lee WG","year":"2013","journal-title":"J Am Chem Soc"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.bmcl.2010.03.006","article-title":"Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives","volume":"20","author":"Leung CS","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1747-0285.2008.00713.x","article-title":"Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor","volume":"72","author":"Li Z","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski CA","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"ref115","first-page":"1","article-title":"Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine","volume":"20","author":"Liu J","year":"2014","journal-title":"J Mol Model"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1126\/science.1163108","article-title":"Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates","volume":"322","author":"Liu S","year":"2008","journal-title":"Science"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcc.10369","article-title":"Improving the efficiency and reliability of free energy perturbation calculations using overlap sampling methods","volume":"25","author":"Lu N","year":"2004","journal-title":"J Comput Chem"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/AAC.05537-11","article-title":"F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis","volume":"56","author":"Lu X","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1021\/jp973084f","article-title":"All-atom empirical potential for molecular modeling and dynamics studies of proteins","volume":"102","author":"MacKerell AD","year":"1998","journal-title":"J Phys Chem B"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/prot.1137","article-title":"Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding","volume":"45","author":"Madrid M","year":"2001","journal-title":"Proteins"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/v2040880","article-title":"HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate","volume":"2","author":"Maga G","year":"2010","journal-title":"Viruses"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20121827","article-title":"Neutralizing antibodies to HIV-1 induced by immunization","volume":"210","author":"McCoy LE","year":"2013","journal-title":"J Exp Med"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?","volume":"53","author":"Mehellou Y","year":"2010","journal-title":"J Med Chem"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/cmdc.201402015","article-title":"Design, synthesis and biological evaluation of 1,3-diarylpropenones as dual inhibitors of HIV-1 reverse transcriptase","volume":"9","author":"Meleddu R","year":"2014","journal-title":"ChemMedChem"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Menendez-Arias L","year":"2013","journal-title":"Antiviral Res"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng XY","year":"2011","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4\u2019-Ethynyl-2-fluoro-2\u2019-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis E","year":"2014","journal-title":"J Biol Chem"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/minf.201000051","article-title":"Rigorous free energy calculations in structure-based drug design","volume":"29","author":"Michel J","year":"2010","journal-title":"Mol Inform"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/nsmb.2194","article-title":"Prospects for an HIV vaccine: leading B cells down the right path","volume":"18","author":"Moir S","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bjp.0707515","article-title":"Towards the development of universal, fast and highly accurate docking\/scoring methods: a long way to go","volume":"153","author":"Moitessier N","year":"2008","journal-title":"Br J Pharmacol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1021\/ci1001982","article-title":"Docking validation resources: protein family and ligand flexibility experiments","volume":"50","author":"Mukherjee S","year":"2010","journal-title":"J Chem Inf Model"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molstruc.2014.12.090","article-title":"Synthesis, structure-activity relationship and molecular docking of cyclohexenone based analogous as potent non-nucleoside reverse-transcriptase inhibitors","volume":"1086","author":"Nazar MF","year":"2015","journal-title":"J Mol Struct"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles RE","year":"2012","journal-title":"J Infect Dis"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman DJ","year":"2012","journal-title":"J Nat Prod"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1021\/ci200117n","article-title":"Predictive power of molecular dynamics receptor structures in virtual screening","volume":"51","author":"Nichols SE","year":"2011","journal-title":"J Chem Inf Model"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/ci900068k","article-title":"Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures","volume":"49","author":"Nichols SE","year":"2009","journal-title":"J Chem Inf Model"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/jcc.20090","article-title":"A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6","volume":"25","author":"Oostenbrink C","year":"2004","journal-title":"J Comput Chem"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1021\/ci010366a","article-title":"Is there a difference between leads and drugs? A historical perspective","volume":"41","author":"Oprea TI","year":"2001","journal-title":"J Chem Inf Comput Sci"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/prot.10028","article-title":"Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock","volume":"46","author":"Osterberg F","year":"2002","journal-title":"Proteins"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1073\/pnas.0404151101","article-title":"Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors","volume":"101","author":"Pata JD","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/j100056a020","article-title":"A comparison of alternative approaches to free-energy calculations","volume":"98","author":"Pearlman DA","year":"1994","journal-title":"J Phys Chem"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-4655(95)00041-D","article-title":"AMBER, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules","volume":"91","author":"Pearlman DA","year":"1995","journal-title":"Comput Phys Commun"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/minf.201200018","article-title":"Pharmacophore identification, molecular docking, virtual screening and in silico ADME studies of non-nucleoside reverse transcriptase inhibitors","volume":"31","author":"Pirhadi S","year":"2012","journal-title":"Mol Inf"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"10235","DOI":"10.1021\/jp102971x","article-title":"Good practices in free-energy calculations","volume":"114","author":"Pohorille A","year":"2010","journal-title":"J Phys Chem B"},{"key":"ref145","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-10-34","article-title":"Novel therapeutic strategies targeting HIV integrase","volume":"10","author":"Quashie PK","year":"2012","journal-title":"BMC Med"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/jm0493921","article-title":"HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies","volume":"48","author":"Ragno R","year":"2005","journal-title":"J Med Chem"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1099\/0022-1317-83-6-1253","article-title":"Human immunodeficiency virus type 2","volume":"83","author":"Reeves JD","year":"2002","journal-title":"J Gen Virol"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/jm8004493","article-title":"Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"51","author":"Ren J","year":"2008","journal-title":"J Med Chem"},{"key":"ref149","first-page":"5633","article-title":"Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases","volume":"275","author":"Ren J","year":"2000","journal-title":"Structural and biochemical analyses"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsb0495-293","article-title":"High resolution structures of HIV-1 RT from four RT-inhibitor complexes","volume":"2","author":"Ren J","year":"1995","journal-title":"Nat Struct Biol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"14394","DOI":"10.1021\/bi981309m","article-title":"Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives","volume":"37","author":"Ren J","year":"1998","journal-title":"Biochemistry"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0969-2126(00)00513-X","article-title":"Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase","volume":"8","author":"Ren J","year":"2000","journal-title":"Structure"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1006\/jmbi.2001.4988","article-title":"Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors","volume":"312","author":"Ren J","year":"2001","journal-title":"J Mol Biol"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"14316","DOI":"10.1074\/jbc.275.19.14316","article-title":"Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding","volume":"275","author":"Ren J","year":"2000","journal-title":"J Biol Chem"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jmb.2003.12.055","article-title":"Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors","volume":"336","author":"Ren J","year":"2004","journal-title":"J Mol Biol"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"E2687","DOI":"10.1073\/pnas.1506755112","article-title":"CD4 mimetics sensitize HIV-1-infected cells to ADCC","volume":"112","author":"Richard J","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1055\/s-2006-941506","article-title":"Integrated in silico tools for exploiting the natural products\u2019 bioactivity","volume":"72","author":"Rollinger JM","year":"2006","journal-title":"Planta Med"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2174\/092986706777442075","article-title":"Strategies for efficient lead structure discovery from natural products","volume":"13","author":"Rollinger JM","year":"2006","journal-title":"Curr Med Chem"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-3-7643-8117-2_6","article-title":"Virtual screening for the discovery of bioactive natural products","volume":"65","author":"Rollinger JM","year":"2008","journal-title":"Prog Drug Res"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1386207054546469","article-title":"Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai medicinal plants database: a combined docking with neural networks approach","volume":"8","author":"Sangma C","year":"2005","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.sbi.2004.10.013","article-title":"Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases","volume":"14","author":"Sarafianos SG","year":"2004","journal-title":"Curr Opin Struct Biol"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized Phase 2 study","volume":"67","author":"Sax PE","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/fvl.11.35","article-title":"HIV-1 reverse transcriptase inhibitors: beyond classic nucleosides and non-nucleosides","volume":"6","author":"Scarth BJ","year":"2011","journal-title":"Future Virol"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"430","DOI":"10.6026\/97320630005430","article-title":"Docking study of HIV-1 reverse transcriptase with phytochemicals","volume":"5","author":"Seal A","year":"2011","journal-title":"Bioinformation"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1359-6446(01)02100-6","article-title":"The emerging importance of predictive ADME simulation in drug discovery","volume":"7","author":"Selick HE","year":"2002","journal-title":"Drug Discov Today"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s12038-007-0140-y","article-title":"Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born\/surface area and absorption, distribution, metabolism and excretion properties","volume":"32","author":"Sengupta D","year":"2007","journal-title":"J Biosci"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman W","year":"2006","journal-title":"J Med Chem"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1367-5931(02)00339-3","article-title":"Lead discovery using molecular docking","volume":"6","author":"Shoichet BK","year":"2002","journal-title":"Curr Opin Chem Biol"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/0003-4819-150-5-200903030-00006","article-title":"Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection","volume":"150","author":"Silverberg MJ","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski G","year":"2014","journal-title":"Pharmacol Rev"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1570162043351093","article-title":"Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding","volume":"2","author":"Sluis-Cremer N","year":"2004","journal-title":"Curr HIV Res"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/pro.5560041026","article-title":"Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity","volume":"4","author":"Smith MBK","year":"1995","journal-title":"Protein Sci"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.virusres.2004.11.011","article-title":"Lethal mutagenesis of HIV","volume":"107","author":"Smith RA","year":"2005","journal-title":"Virus Res"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.bbrc.2007.11.036","article-title":"Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors","volume":"365","author":"Spallarossa A","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10822-011-9533-y","article-title":"Surflex-Dock: docking benchmarks and real-world application","volume":"26","author":"Spitzer R","year":"2012","journal-title":"J Comput Aided Mol Des"},{"key":"ref176","first-page":"2","author":"Spreen W","year":"2013"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350100603S01","article-title":"An introduction to nucleoside and nucleotide analogues","volume":"6","author":"Squires KE","year":"2001","journal-title":"Antivir Ther"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"17395","DOI":"10.1074\/jbc.274.25.17395","article-title":"DNA polymerases: structural diversity and common mechanisms","volume":"274","author":"Steitz TA","year":"1999","journal-title":"J Biol Chem"},{"key":"ref179","doi-asserted-by":"crossref","DOI":"10.1021\/ja00172a038","article-title":"A general treatment of solvation for molecular mechanics","volume":"112","author":"Still WC","year":"1990","journal-title":"J Am Chem Soc"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.00353-10","article-title":"Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors","volume":"84","author":"Su H-P","year":"2010","journal-title":"J Virol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/acs.jcim.5b00019","article-title":"QSAR modeling using large-scale databases: case study for HIV-1 reverse transcriptase inhibitors","volume":"55","author":"Tarasova OA","year":"2015","journal-title":"J Chem Inf Model"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1020155510718","article-title":"A review of protein-small molecule docking methods","volume":"16","author":"Taylor RD","year":"2002","journal-title":"J Comput Aided Mol Des"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm051197e","article-title":"MolDock: a new technique for high-accuracy molecular docking","volume":"49","author":"Thomsen R","year":"2006","journal-title":"J Med Chem"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0968-0896(99)00012-7","article-title":"Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase","volume":"7","author":"Titmuss SJ","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2174\/092986710792065045","article-title":"HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development","volume":"17","author":"Tramontano E","year":"2010","journal-title":"Curr Med Chem"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/jm049092j","article-title":"Virtual screening workflow development guided by the \u201creceiver operating characteristic\u201d curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4","volume":"48","author":"Triballeau N","year":"2005","journal-title":"J Med Chem"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2174\/1568026033451754","article-title":"Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design","volume":"3","author":"Tronchet JM","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott O","year":"2010","journal-title":"J Comput Chem"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nsmb760","article-title":"Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir","volume":"11","author":"Tuske S","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"ref190","series-title":"Global report. UNAIDS report on the global AIDS epidemic 2013","year":"2013"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ejmech.2010.12.022","article-title":"Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads","volume":"46","author":"Vadivelan S","year":"2011","journal-title":"Eur J Med Chem"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1166\/jpsp.2014.1024","article-title":"Quantitative structure-activity relationships: a novel approach of drug design and discovery","volume":"1","author":"Vaidya A","year":"2014","journal-title":"J Pharm Sci Pharmacol"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/S0006-3495(97)78317-6","article-title":"Protein dynamics derived from clusters of crystal structures","volume":"73","author":"van Aalten DM","year":"1997","journal-title":"Biophys J"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible and free","volume":"26","author":"Van Der Spoel D","year":"2005","journal-title":"J Comput Chem"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk ML","year":"2003","journal-title":"Proteins"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/md8122871","article-title":"Potential anti-HIV agents from marine resources: an overview","volume":"8","author":"Vo TS","year":"2010","journal-title":"Mar Drugs"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"38424","DOI":"10.1074\/jbc.M406241200","article-title":"Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1","volume":"279","author":"Wang LZ","year":"2004","journal-title":"J Biol Chem"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/135965350701200510","article-title":"Abacavir plasma pharmacokinetics in the absence and presence of atazanavir\/ritonavir or lopinavir\/ritonavir and vice versa in HIV-infected patients","volume":"12","author":"Waters LJ","year":"2007","journal-title":"Antivir Ther"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.med.53.052901.131947","article-title":"Rational approach to AIDS drug design through structural biology","volume":"53","author":"Wlodawer A","year":"2002","journal-title":"Annu Rev Med"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: challenges and recent advances","volume":"15","author":"Yang SY","year":"2010","journal-title":"Drug Discov Today"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/138955708786141052","article-title":"Recent advances in the research of HIV-1 RNase H inhibitors","volume":"8","author":"Yu F","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jmr.2266","article-title":"Latest developments in molecular docking: 2010-2011 in review","volume":"26","author":"Yuriev E","year":"2013","journal-title":"J Mol Recognit"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"9492","DOI":"10.1021\/ja8019214","article-title":"Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations","volume":"130","author":"Zeevaart JG","year":"2008","journal-title":"J Am Chem Soc"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/med.20241","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity and impliations for drug design","volume":"33","author":"Zhan P","year":"2013","journal-title":"Med Res Rev"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2174\/138955710792007222","article-title":"Cosalane and its analogues: a unique class of anti-HIV agents","volume":"10","author":"Zhan P","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.tips.2013.08.004","article-title":"Computational methods for drug design and discovery: focus on China","volume":"34","author":"Zheng MY","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/prot.10233","article-title":"Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase","author":"Zhou Z","year":"2002","journal-title":"Proteins"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/mioc\/v110n7\/0074-0276-mioc-110-7-0847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:28:55Z","timestamp":1748687335000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762015000700847&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":207,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0074-02762015000700847"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760150239","relation":{},"ISSN":["0074-0276"],"issn-type":[{"value":"0074-0276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}